jRCT2021230034招募中不适用
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Nemolizumab in Patients with Acquired Reactive Perforating Collagenosis
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 21
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Patients aged 18 years or older who have been diagnosed with acquired reactive perforating collagen fibrosis according to the diagnostic criteria of the Clinical Practice Guide for Perforated Dermatoses (2020)
排除标准
- •Patients with immune deficiency
- •Patients with body weight less than 30.0kg
- •Patients with Hepatitis B virus or hepatitis C virus infection
- •Patients with Evidence of tuberculosis (TB) infection
- •Pregnant or lactating women.
结局指标
主要结局
-
Peak pruritus-Numeric rate scale (PP-NRS)
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
不适用
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of Two Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to MethotrexateRheumatoid ArthritisEUCTR2008-000742-30-HURigel Pharmaceuticals, Inc.420
已完成
不适用
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remissio-C56 Malignant neoplasm of ovaryMalignant neoplasm of ovaryC56PER-133-08GENENTECH, INC.,
已完成
不适用
Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3) Taski-3-M069M069PER-100-08Rigel Pharmaceuticals, Inc.,
进行中（未招募）
不适用
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study Of Xolair (Omaluzimab) In Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Anithistamine Treatment (H1)Chronic Idiopathic UrticariaMedDRA version: 9.1Level: LLTClassification code 10009159Term: Chronic urticariaMedDRA version: 9.1Level: LLTClassification code 10021247Term: Idiopathic urticariaEUCTR2009-009498-87-DEGenentech, Inc.76
进行中（未招募）
不适用
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis Who Have Failed at Least One BiologicMedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2008-000743-34-BERigel Pharmaceuticals, Inc.195